美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

百济神州

291.47

-4.9900-1.68%

盘后：291.470.00000.00%16:39 EDT

成交量：17.12万

成交额：4,989.66万

市值：345.83亿

市盈率：-78.71

高：293.17

开：289.73

低：287.00

收：296.46

数据加载中...

总览公司新闻公告

百济神州7月21日成交额为9303.69万美元

公募基金2025年二季报全扫描【国信金工】

量化藏经阁

中证港股通生物科技主题指数报1824.70点，前十大权重包含百济神州等

I-Mab不足700万美元收购BridgeHealth，斩获CLDN18.2上游权利

CPHI制药在线

医药行业迎来政策东风，投资者加速寻找“潜力股”

5大创新药企人效PK：恒瑞、百济、石药、中生和翰森

百济神州(ONC)盘前涨近4% 机构料公司第二季收入按年升33%至12亿美元

小细胞肺癌治疗重大突破！百济神州&安进双抗新药在华申报上市

百济神州7月17日成交额为2.34亿美元

港股异动 | 百济神州(06160)再涨超6% DLL3/CD3双特异性抗体塔拉妥单抗上市申报获受理

DLL3/CD3双特异性抗体塔拉妥单抗申报上市

百济神州-U股价微跌0.56% 生物制药板块活跃度受关注

小细胞肺癌或将迎来首个BiTE新疗法，百济神州塔拉妥单抗申报上市

高管减持迪哲医药另一面：全球化战略会是下个百济神州吗？【医药视界】

眼看要赚钱，资金为什么减持百济神州？

股市动态分析

百济神州7月15日成交额为1.81亿美元

医药股2025中报业绩预告：53家净利润增长，42家预计亏损

生物制品圈

科创成长层改革推进券商系统升级及风险揭示书签署有序展开

2025全球制药50强排名揭晓，中国药企表现亮眼！

医保商保双目录调整生物医药午后涨幅扩大荣昌生物涨逾8%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/ONC/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":291.47,"timestamp":1753473600000,"preClose":296.46,"halted":0,"volume":171194,"hourTrading":{"tag":"盘后","latestPrice":291.47,"preClose":291.47,"latestTime":"16:39 EDT","volume":1979,"amount":576814.86,"timestamp":1753475983218},"delay":0,"floatShares":75541600,"shares":118650120,"eps":-3.70325,"marketStatus":"休市中","change":-4.99,"latestTime":"07-25 16:00:00 EDT","open":289.73,"high":293.165,"low":287,"amount":49896623.98421,"amplitude":0.020795,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1753689600000},"marketStatusCode":7,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":296.46,"preHourTrading":{"tag":"盘前","latestPrice":291,"preClose":296.46,"latestTime":"09:28 EDT","volume":38,"amount":11165.538480000001,"timestamp":1753450080032},"postHourTrading":{"tag":"盘后","latestPrice":291.47,"preClose":291.47,"latestTime":"16:39 EDT","volume":1979,"amount":576814.86,"timestamp":1753475983218},"volumeRatio":0.40463067027862526,"impliedVol":0.4268,"impliedVolPercentile":0.4714},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75541600,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":0.40463067027862526,"shares":118650120,"dividePrice":0,"high":293.165,"amplitude":0.020795,"preClose":296.46,"low":287,"week52Low":155.75,"pbRate":"9.88","psRate":"8.28","week52High":300,"institutionHeld":0,"latestPrice":291.47,"eps":-3.70325,"divideRate":0,"volume":171194,"delay":0,"ttmEps":-3.70325,"open":289.73,"prevYearClose":184.71,"prevWeekClose":294.55,"prevMonthClose":242.07,"prevQuarterClose":242.07,"fiveDayClose":294.55,"twentyDayClose":254.49,"sixtyDayClose":249.77,"earningDate":1754409600000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2553281332","title":"百济神州7月21日成交额为9303.69万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553281332","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553281332?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 12:35","pubTimestamp":1753158948,"startTime":"0","endTime":"0","summary":"美东时间2025年7月21日，百济神州成交额为9303.69万美元，成交额较昨日减少64.86%，当日成交量为32.00万股。百济神州于2025年7月21日跌0.89%，报291.93美元，该股过去5个交易日涨15.78%，年初至今涨58.05%，过去60日涨17.18%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722123551a45b447d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722123551a45b447d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4526"],"gpt_icon":0},{"id":"2553008144","title":"公募基金2025年二季报全扫描【国信金工】","url":"https://stock-news.laohu8.com/highlight/detail?id=2553008144","media":"量化藏经阁","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553008144?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 08:06","pubTimestamp":1753142805,"startTime":"0","endTime":"0","summary":"一基金仓位监控在跟踪基金仓位变化时，由于2015年四季度以前股票型基金仓位规定下限为60%，在这之后规定为80%。截至2025年二季报，科技类板块配置权重依旧最高，最新一期配置权重为37.42%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722082610a6b94be8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722082610a6b94be8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4614","ONC","09988","688428","09969","600519","03750","BK4099","YANG","BK4588","688235","BYDDY","EVS.SI","BK4585"],"gpt_icon":0},{"id":"2553984472","title":"中证港股通生物科技主题指数报1824.70点，前十大权重包含百济神州等","url":"https://stock-news.laohu8.com/highlight/detail?id=2553984472","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553984472?lang=zh_cn&edition=fundamental","pubTime":"2025-07-21 18:40","pubTimestamp":1753094430,"startTime":"0","endTime":"0","summary":"数据统计显示，中证港股通生物科技主题指数近一个月上涨20.61%，近三个月上涨60.82%，年至今上涨93.22%。从中证港股通生物科技主题指数持仓的市场板块来看，香港证券交易所占比100.00%。从中证港股通生物科技主题指数持仓样本的行业来看，化学药占比41.65%、生物药品占比38.23%、制药与生物科技服务占比17.68%、医疗器械占比2.44%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721205936a4599dc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721205936a4599dc7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01093","06990","BK4139","01530","06160","BK4526","688235","03692","02359","01801","BK4614","YANG","01177","ONC","SBHMY"],"gpt_icon":0},{"id":"2553420035","title":"I-Mab不足700万美元收购BridgeHealth，斩获CLDN18.2上游权利","url":"https://stock-news.laohu8.com/highlight/detail?id=2553420035","media":"CPHI制药在线","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553420035?lang=zh_cn&edition=fundamental","pubTime":"2025-07-21 16:01","pubTimestamp":1753084901,"startTime":"0","endTime":"0","summary":"而BridgeHealth所持有的正是givastomig分子中靶向CLDN18.2的\"亲本抗体\"全部上游IP。一家\"小而关键\"的技术原点公司BridgeHealth并非传统意义上的biotech，它更像一个围绕单克隆抗体发现平台而生的IP公司：成立6年，核心资产是CLDN18.2亲本抗体、2项PCT专利族及若干Know-how。表面上看，交易总价不足700万美元，但考虑到BridgeHealth此前对givastomig的里程碑提成原本可能高达数千万美元级别，此次收购的净现值其实远超账面数字。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721170922a459079c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721170922a459079c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK4139","BK4526","BK4535","BK4505","06160","IMAB","ONC"],"gpt_icon":0},{"id":"2553425613","title":"医药行业迎来政策东风，投资者加速寻找“潜力股”","url":"https://stock-news.laohu8.com/highlight/detail?id=2553425613","media":"制药网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553425613?lang=zh_cn&edition=fundamental","pubTime":"2025-07-21 13:44","pubTimestamp":1753076686,"startTime":"0","endTime":"0","summary":"【制药网 市场分析】“近期，国家医保局和国家卫生健康委印发了《支持创新药高质量发展的若干措施》，有行业人士表示，这一政策释放出三个信号：一是通过医保谈判和商保目录优化，创新药价格压力得到缓解，商业化空间显著扩大；二是鼓励差异化创新，淘汰低端产能，行业集中度进一步提升；三是推动药企从“成本压缩”转向“技术溢价”。在此背景下，具备研发能力、差异化管线布局及商业化优势的企业将优先受益，投资者可以关注恒瑞","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072113452797ae2d12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072113452797ae2d12&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","BK4526"],"gpt_icon":0},{"id":"2552410416","title":"5大创新药企人效PK：恒瑞、百济、石药、中生和翰森","url":"https://stock-news.laohu8.com/highlight/detail?id=2552410416","media":"药事纵横","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552410416?lang=zh_cn&edition=fundamental","pubTime":"2025-07-20 08:04","pubTimestamp":1752969841,"startTime":"0","endTime":"0","summary":"中国创新药正式进入DEEPSEEK时刻！作为中国创新药的标杆，恒瑞、百济、石药、中生和翰森，近年在NowCo与licenseout方面也是动作频频，快速走向全球。营收情况创新药行业的“效率竞赛”中，营收与净利润不仅是企业生存的根本。肿瘤线中，PD-1卡瑞利珠单抗已上市，ADC药物SHR-A1811目前为乳腺癌III期临床、CDK4/6抑制剂SHR6390处于乳腺癌II期临床阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250720081033a456037a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250720081033a456037a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU0072913022.USD","LU0501845795.SGD","LU1807302812.USD","LU0315179316.USD","LU1226288170.HKD","IE00B5MMRT66.SGD","688235","LU0326950275.SGD","LU1008478684.HKD","BK1161","600276","BK1191","LU1152091168.USD","BK1589","LU0140636845.USD","LU1960683339.HKD","ONC","LU0067412154.USD","LU1152091754.HKD","LU1951186391.HKD","LU1993786604.SGD","LU1226287792.SGD","IE00B031HY20.USD","LU1226287529.USD","IE00B543WZ88.USD","LU0880133367.SGD","01177","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","LU1226288253.USD","03692","BK1515","BK1521","BK1574","IE00BZ08YT58.USD","IE0008369823.USD","SG9999004220.SGD","LU1226287875.USD","01093","06978","IE0008368742.USD"],"gpt_icon":0},{"id":"2552626304","title":"百济神州(ONC)盘前涨近4% 机构料公司第二季收入按年升33%至12亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552626304","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552626304?lang=zh_cn&edition=fundamental","pubTime":"2025-07-18 19:26","pubTimestamp":1752837999,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州(ONC)盘前涨近4%，截至发稿，报301.260美元 。 消息面上，野村发表报告，料百济神州第二季收入按年升33%至12亿美元，与市场预期一致。该行预测百悦泽维持市场领导地位，次季销售按年升39%至8.84亿美元，其中美欧销售分别按年升35%及80%，至6.47亿及1.4亿美元。百泽安内地市场销售料按年升15%至1.82亿美元。此外，摩根大通分析师Jessica Fye维持百济神州买入评级，并将目标价从321美元上调至345美元。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"290592","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK1161","ONC","BK4526","LU2328871848.SGD","BK1500","06160","BK1583","LU0588546209.SGD","BK0239","BK4139","LU1969619763.USD","688235","LU0307460666.USD"],"gpt_icon":0},{"id":"2552462341","title":"小细胞肺癌治疗重大突破！百济神州&安进双抗新药在华申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2552462341","media":"药事纵横","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552462341?lang=zh_cn&edition=fundamental","pubTime":"2025-07-18 17:00","pubTimestamp":1752829200,"startTime":"0","endTime":"0","summary":"7月16日，CDE官网显示，百济神州与安进合作开发的注射用塔拉妥单抗上市申请正式获受理。小细胞肺癌的后线治疗选择极为有限。医学界长期将小细胞肺癌后线治疗视为公认的难治领域，这一困境已持续数十年未取得实质性突破。这种创新机制使塔拉妥单抗成为首个用于实体瘤的BiTE药物，为小细胞肺癌治疗开辟了全新路径。百济神州与安进已达成全球肿瘤战略合作，共同推进塔拉妥单抗在中国的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718191410a6b2101b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718191410a6b2101b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","LU1983299246.USD","BK4533","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU2089984988.USD","BK4581","IE00BFTCPJ56.SGD","LU2242652126.USD","BK4534","LU0320765992.SGD","IE00BJJMRZ35.SGD","LU0122379950.USD","LU0289739699.SGD","LU1023059063.AUD","688235","IE0009355771.USD","AMGN","SG9999001440.SGD","BK4599","LU2468319806.SGD","LU2242646821.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","06160","LU0889565916.HKD","ONC","LU1057294990.SGD","BK4566","LU0058720904.USD","LU2112291526.USD","BK4585","LU1571399168.USD","LU0109394709.USD","LU1061106388.HKD","LU0868494617.USD"],"gpt_icon":0},{"id":"2552459051","title":"百济神州7月17日成交额为2.34亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552459051","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552459051?lang=zh_cn&edition=fundamental","pubTime":"2025-07-18 12:31","pubTimestamp":1752813112,"startTime":"0","endTime":"0","summary":"美东时间2025年7月17日，百济神州成交额为2.34亿美元，成交额较昨日增加72.38%，当日成交量为80.49万股。百济神州于2025年7月17日涨4.01%，报290.35美元，该股过去5个交易日涨14.59%，年初至今涨57.19%，过去60日涨26.67%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718123153a6b135fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718123153a6b135fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4526"],"gpt_icon":0},{"id":"2552742401","title":"港股异动 | 百济神州(06160)再涨超6% DLL3/CD3双特异性抗体塔拉妥单抗上市申报获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2552742401","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552742401?lang=zh_cn&edition=fundamental","pubTime":"2025-07-17 09:58","pubTimestamp":1752717499,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州再涨超6%，截至发稿，涨6.28%，报176.1港元，成交额4.26亿港元。消息面上，7月16日，国家药品监督管理局药品审评中心网站显示，百济神州的注射用塔拉妥单抗上市申报获受理。塔拉妥单抗作为同类首创的DLL3/CD3双特异性抗体，或将为小细胞肺癌患者的后线治疗带来突破性进展。据悉，塔拉妥单抗由安进公司研发。未来，双方将继续拓展塔拉妥单抗的应用范围，加速更多适应症申报上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1318805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4139","BK4526","06160","BK1161","BK1588","BK1500","BK0239","ONC","LU0307460666.USD","LU2328871848.SGD","LU0588546209.SGD","LU1969619763.USD","688235"],"gpt_icon":0},{"id":"2552179075","title":"DLL3/CD3双特异性抗体塔拉妥单抗申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2552179075","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552179075?lang=zh_cn&edition=fundamental","pubTime":"2025-07-17 09:02","pubTimestamp":1752714127,"startTime":"0","endTime":"0","summary":"7月16日，国家药品监督管理局药品审评中心网站显示，百济神州的注射用塔拉妥单抗上市申报获受理。塔拉妥单抗作为同类首创的DLL3/CD3双特异性抗体，或将为小细胞肺癌患者的后线治疗带来突破性进展。据悉，塔拉妥单抗由安进公司研发。未来，双方将继续拓展塔拉妥单抗的应用范围，加速更多适应症申报上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717090448a44fb768&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717090448a44fb768&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1223083913.SGD","688235","BK4139","BK4526","LU1223082196.USD","CDE","LU1223082519.USD","06160","BK4017","ONC"],"gpt_icon":0},{"id":"2552412721","title":"百济神州-U股价微跌0.56% 生物制药板块活跃度受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2552412721","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552412721?lang=zh_cn&edition=fundamental","pubTime":"2025-07-17 01:56","pubTimestamp":1752688566,"startTime":"0","endTime":"0","summary":"百济神州-U7月16日收盘报239.94元，较前一交易日下跌0.56%。当日股价波动区间为237.79元至246.28元，成交金额达5.01亿元。该公司属于生物制品行业，专注于创新型分子靶向药物和肿瘤免疫药物的研发。作为一家全球性生物科技公司，百济神州在肿瘤治疗领域拥有多个在研产品管线。7月16日数据显示，百济神州-U主力资金净流出2927.45万元。该股当前总市值为3694.74亿元，流通市值276.06亿元。风险提示：股市有风险，投资需谨慎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071702031197a8b94d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071702031197a8b94d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK0239","ONC","06160"],"gpt_icon":0},{"id":"2551140802","title":"小细胞肺癌或将迎来首个BiTE新疗法，百济神州塔拉妥单抗申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2551140802","media":"新浪医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551140802?lang=zh_cn&edition=fundamental","pubTime":"2025-07-16 19:15","pubTimestamp":1752664513,"startTime":"0","endTime":"0","summary":"2025年7月16日，国家药品监督管理局药品审评中心网站显示，百济神州的注射用塔拉妥单抗上市申报获受理。SCLC约占所有肺癌病例的15%,，其中大约70%的SCLC患者初始诊断时即为ES-SCLC。据悉，塔拉妥单抗由安进公司研发。未来，双方将继续拓展塔拉妥单抗的应用范围，加速更多适应症申报上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716192041a44e9ea7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716192041a44e9ea7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","688235","BK4526","06160","ONC"],"gpt_icon":0},{"id":"2551576142","title":"高管减持迪哲医药另一面：全球化战略会是下个百济神州吗？【医药视界】","url":"https://stock-news.laohu8.com/highlight/detail?id=2551576142","media":"投资者网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551576142?lang=zh_cn&edition=fundamental","pubTime":"2025-07-16 18:01","pubTimestamp":1752660075,"startTime":"0","endTime":"0","summary":"减持释放什么信号迪哲医药进入一个高层减持密集期。其中，吴清漪减持金额超1900万元，股份来源于股权激励及二级市场增持。截至目前，公司仍无控股股东、实际控制人。获批上市后，该药被成功纳入医保。公司表示，两款药品纳入医保目录后，销量大幅增加。最为市场熟知的，是百济神州的泽布替尼。受此因素，该药成功在欧美获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716180622a6ad36ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716180622a6ad36ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","ONC","688235","BK4139","BK4526","06160"],"gpt_icon":0},{"id":"2552215179","title":"眼看要赚钱，资金为什么减持百济神州？","url":"https://stock-news.laohu8.com/highlight/detail?id=2552215179","media":"股市动态分析","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552215179?lang=zh_cn&edition=fundamental","pubTime":"2025-07-16 16:52","pubTimestamp":1752655962,"startTime":"0","endTime":"0","summary":"近日，二季度陆股通数据出炉，北向资金减持百济神州717.19万股，对应市值达17.20亿元。近几年，百济神州大股东也在陆续减持。自2023年6月8日起，陪伴公司十一年的高瓴资本开始多次减持百济神州，通过集中竞价与大宗交易等方式，在2023年6月8日至2024年12月2日期间减持约2199.73万股，持股比例从10.61%减少至9.02%。2025年3月3日至4日，高瓴资本再度减持3224万股，持股比例降至6.66%。百悦泽已在全球70多个市场获批，共计超过18万例患者接受治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716170142a44e5022&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716170142a44e5022&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC","688235","BK0239"],"gpt_icon":0},{"id":"2551149731","title":"百济神州7月15日成交额为1.81亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551149731","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551149731?lang=zh_cn&edition=fundamental","pubTime":"2025-07-16 12:39","pubTimestamp":1752640775,"startTime":"0","endTime":"0","summary":"美东时间2025年7月15日，百济神州成交额为1.81亿美元，成交额较昨日增加575.75%，当日成交量为67.44万股。百济神州于2025年7月15日涨6.96%，报269.7美元，该股过去5个交易日涨10.32%，年初至今涨46.01%，过去60日涨18.22%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716123942a44dcfb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716123942a44dcfb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","BK4139"],"gpt_icon":0},{"id":"2551114238","title":"医药股2025中报业绩预告：53家净利润增长，42家预计亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2551114238","media":"生物制品圈","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551114238?lang=zh_cn&edition=fundamental","pubTime":"2025-07-16 11:56","pubTimestamp":1752638187,"startTime":"0","endTime":"0","summary":"CRO龙头企业药明康德系披露业绩预告的医药股中，预告归属净利润最高的个股，公司预计上半年实现净利85.61亿元，同比预增101.92%。业绩亮点：2025 年中报归母净利润预计同比增长 145.67%~170.23%。0242股净利预计亏损东方财富Choice数据显示，按预告净利润下限统计，共有42只医药股预计2025年上半年将出现亏损。其中，达安基因、海南海药预计亏损金额居前。这也是联环药业自2003年上市以来首次半年度净利亏损。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716121157a6ac870d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716121157a6ac870d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600513","159938","01177","ONC","600196","01801","600276","688235","02196","01276","01877","603392","06160","688180","SBHMY","603259"],"gpt_icon":0},{"id":"2551119280","title":"科创成长层改革推进 券商系统升级及风险揭示书签署有序展开","url":"https://stock-news.laohu8.com/highlight/detail?id=2551119280","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551119280?lang=zh_cn&edition=fundamental","pubTime":"2025-07-16 11:13","pubTimestamp":1752635582,"startTime":"0","endTime":"0","summary":"上交所方面正组织风险揭示书签署工作，并修订相关指南，新增《科创板科创成长层企业股票投资风险揭示书必备条款》，明确未盈利企业存在的各类投资风险。上交所下发通知要求券商完善适当性管理工作，包括完成风险揭示书签署及系统准备，给予投资者充分阅读时间，并通过多种渠道开展投资者教育。上交所将持续督促券商并开展监督检查。7月14日，上交所举办专题培训会，120家券商330余名相关负责人参会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","688538","688176","688322","688702","688515","01877","688277","688469","02402","688382","688192","ONC","688316","688343","688512","688327","688549","688221","688220","688256","688280","688266","688197","688387","688443","BK0239","688302","688561","688373","688165","000690.SH","09969"],"gpt_icon":0},{"id":"2551216032","title":"2025全球制药50强排名揭晓，中国药企表现亮眼！","url":"https://stock-news.laohu8.com/highlight/detail?id=2551216032","media":"医药地理","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551216032?lang=zh_cn&edition=fundamental","pubTime":"2025-07-15 19:46","pubTimestamp":1752580012,"startTime":"0","endTime":"0","summary":"近日，美国《制药经理人》杂志公布了2025全球制药企业50强排名。这一榜单依据2024年度处方药业务全球销售、核心产品收入以及研发投入等指标进行排名。中国药企上榜情况概览此次上榜的6家中国药企中，云南白药排名第33位，与去年持平，位居中国药企榜首。华东医药首次上榜，排名第41位。2025全球制药50强榜单中国药企的亮眼表现，是中国制药行业发展的一个重要里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715205051a44c7785&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715205051a44c7785&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01093","BK0239","600276","688235","01177","SBHMY","06160","ONC","01276"],"gpt_icon":0},{"id":"2551156152","title":"医保商保双目录调整 生物医药午后涨幅扩大 荣昌生物涨逾8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551156152","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551156152?lang=zh_cn&edition=fundamental","pubTime":"2025-07-15 14:18","pubTimestamp":1752560315,"startTime":"0","endTime":"0","summary":"截至发稿，荣昌生物涨8.37%，石药集团涨7.26%，诺诚健华涨6.95%，百济神州涨6.43%，中国生物制药涨4.61%，信达生物涨3.66%。消息面上，2025年国家基本医疗保险，生育保险和工伤保险药品目录及商业健康保险创新药品目录调整7月11日正式启动。世纪证券指出，创新药商保目录意味着国内医药多元支付体系重构，商业健康险将在创新药支付方面扮演更为重要的角色，高价创新药可及性有望进一步提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071514191497a6a43d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071514191497a6a43d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0008369823.USD","BK1583","LU1226288170.HKD","SG9999004220.SGD","IE00BZ08YR35.GBP","LU0501845795.SGD","IE00BZ08YT58.USD","BK1515","LU0140636845.USD","LU1226287792.SGD","09969","IE00BZ08YS42.EUR","01801","LU1969619763.USD","SBHMY","LU1951186391.HKD","LU0326950275.SGD","LU0072913022.USD","LU1152091168.USD","IE00B5MMRT66.SGD","LU1807302812.USD","688428","BK1191","688235","688331","LU0880133367.SGD","09995","LU0067412154.USD","01093","06160","BK1161","IE00B031HY20.USD","LU1008478684.HKD","LU1993786604.SGD","BK1574","01177","LU1226287529.USD","IE0008368742.USD","LU1226288253.USD","LU1226287875.USD","BK1521","LU1960683339.HKD","LU2328871848.SGD","LU1152091754.HKD","ONC","IE00B543WZ88.USD","LU0315179316.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":2,"totalSize":166,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盘前","dateTimestamp":1756526400000,"actualEps":null},{"date":"2025-08-06","symbol":"ONC","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":0.48,"defaultRemindTime":1754467200000,"name":null,"time":"","dateTimestamp":1754452800000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盘前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.6364,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":22,"updateTime":1748318400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-07-25","current":-89.648478,"percent":0.003448,"low":-89.808695,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"high":-19.234246,"avg":-41.089589,"sd":19.328162,"marketCap":35175014575},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575}],"updateTime":1753563962847}}}